| 1 | Cancer profiles in China and comparisons with the USA:a comprehensive analysis in the incidence,mortality,survival,staging,and attribution to risk factors显示文摘China faces a disproportionate cancer burden to the population size and is undergoing a transition in the cancer spectrum.We extracted data in five aspects of cancer incidence,mortality,survival,staging distributions,and attribution to risk factors in China,the USA and worldwide from open-source databases.We conducted a comprehensive secondary analysis of cancer profiles in China in the above aspects,and compared cancer statistics between China and the USA.A total of 4,546,400 new cancer cases and 2,992,600 deaths occurred in China in 2020,accounting for 25.1%and 30.2%of global cases,respectively.Lifestyle-related cancers including lung cancer,colorectal cancer,and breast cancer showed an upward trend and have been the leading cancer types in China.41.6%of new cancer cases and 49.3%of cancer deaths occurred in digestive-system cancers in China,and the cancers of esophagus,nasopharynx,liver,and stomach in China accounted for over 40%of global cases.Infection-related cancers showed the highest population-attributable fractions among Chinese adults,and most cancers could be attributed to behavioral and metabolic factors.The proportions of stage I for most cancer types were much higher in the USA than in China,except for esophageal cancer(78.2%vs.41.1%).The 5-year relative survival rates in China have improved substantially during 2000–2014,whereas survival for most cancer types in the USA was significantly higher than in China,except for upper gastrointestinal cancers.Our findings suggest that although substantial progress has been made in cancer control,especially in digestive system cancers in China,there was still a considerable disparity in cancer burden between China and the USA.More robust policies on risk factors and standardized screening practices are urgently warranted to curb the cancer growth and improve the prognosis for cancer patients. | Siyi He Changfa Xia He Li Maomao Cao Fan Yang Xinxin Yan Shaoli Zhang Yi Teng Qianru Li Wanqing Chen | 2024 | Science China(Life Sciences)2024，67，1： | 2 |
| 2 | 乳腺癌患者血清GP73、miR-27a水平的变化及其与临床病理、化疗疗效的相关性显示文摘目的 分析乳腺癌患者血清高尔基体蛋白73 (GP73)、微小RNA-27a (miR-27a)水平变化及其与临床病理特征、化疗疗效的相关性。方法 选取2021年10月至2023年1月南阳市中心医院收治的80例乳腺癌患者作为研究组,另选取同期健康女性志愿者80例作为对照组。比较两组受检者以及研究组不同临床病理特征患者的血清GP73、miR-27a水平,并比较研究组不同化疗疗效患者化疗前后的血清GP73、miR-27a水平及变化值(△GP73、△miR-27a),采用Spearman相关法分析化疗前血清GP73、miR-27a水平与临床病理特征相关性,以及△GP73、△miR-27a与化疗疗效的相关性。结果 研究组患者的血清GP73、miR-27a水平分别为(121.35±40.12) ng/L、0.71±0.20,明显高于对照组的(47.68±15.29) ng/L、0.21±0.07,差异均有统计学意义(P<0.05);研究组患者中,不同临床分期、分化程度、肿瘤直径、淋巴结转移患者血清GP73、miR-27a水平比较差异均有统计学意义(P<0.05);经Spearman相关法分析结果显示,研究组血清GP73、miR-27a水平与乳腺癌临床分期、肿瘤直径、淋巴结转移呈正相关(P<0.05),与分化程度呈负相关(P<0.05);无效者化疗前后的血清GP73、miR-27a水平明显高于有效者,差异均有统计学意义(P<0.05);无效者△GP73、△miR-27a分别为13.52±3.16、0.07±0.02,明显低于有效者的21.31±5.42、0.12±0.03,差异均有统计学意义(P<0.05);经Spearman相关法分析结果显示,△GP73、△miR-27a与化疗疗效呈正相关(r=0.658、0.714,P<0.05)。结论 血清GP73、miR-27a水平与乳腺癌临床病理特征、化疗疗效密切相关,可以作为评估病情进展及化疗疗效的潜在指标。 | 陆佳团 王征 张浩 唐梦雨 | 2024 | 海南医学2024，35，5： | 0 |
| 3 | 基于DCE-MRI评价乳腺癌新辅助化疗疗效的研究进展显示文摘乳腺癌年新增患病人数超226万,为女性最常见的恶性肿瘤。准确并尽早评估乳腺癌患者乳腺癌新辅助化疗(neoadjuvant chemotherapy,NAC)疗效,对患者进行治疗分层和预后判断至关重要。目前,动态对比增强磁共振成像(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)是临床推荐用于NAC疗效评估的首选检查手段。伴随着大数据挖掘技术逐步应用于乳腺癌NAC疗效评估,近年来已有多项研究致力于探索DCE-MRI的定性、半定量及定量分析在乳腺癌NAC疗效评价中价值。本文基于DCE-MRI的定性、半定量及定量特征,对其在评估乳腺癌NAC中的主要进展及存在问题进行综述。 | 张弛 许国辉 | 2023 | 肿瘤预防与治疗2023，36，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员